17.47
+5.88%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About DocMorris
Its shares trade on SIX under the ticker DOCM.SW. It has been listed since 6 July 2017. In the fiscal year to 31 December 2025, it reported revenue of CHF 1.12bn and a net loss of CHF 134.4m. At that date it held total assets of CHF 825.4m and shareholders' equity of CHF 409.1m.
Zur Rose Group AG engages in the operation of an e-commerce pharmacy and acts as a medical wholesaler in Switzerland. The company is headquartered in Frauenfeld, Thurgau. The company went IPO on 2017-07-06. The firm focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The firm's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The firm operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Food & Staples Retailing
- Listed since
- 6 Jul 2017
- Employees
- 1,960
- Website
- zurrosegroup.com ↗
Leadership
Pay as last reported
- Mr. Walter OberhaensliNon-Executive Chairman of the Board, since 1996CHF 379,000
- Mr. Walter HessChief Executive Officer, Member of the Executive Board, Head GermanyCHF 1.8m
- Prof. Stefan FeuersteinNon-Executive Independent Vice Chairman of the Board of DirectorsCHF 207,000
- Mr. Daniel WueestChief Financial Officer
- Mr. Kaspar NiklausChief Operations Officer, Member of the Executive Board
- Mr. Pablo Ros GomezChief Technology Officer
- Mr. David MasoHead - Europe, Member of the Executive Board
- Prof. Dr. Andrea BelligerNon-Executive Independent Member of the Board of DirectorsCHF 166,000
- Dr. Christian MielschNon-Executive Independent Member of the Board of DirectorsCHF 190,000
- Ms. Hu RongrongNon-Executive Independent Member of the Board of DirectorsCHF 164,000
- Mr. Florian SeubertNon-Executive Independent Member of the Board of DirectorsCHF 161,000
- Dr. Daniel GrigatHead of Investor Relations and Sustainability, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 61
- Environment
- 44
- Social
- 50
- Governance
- 89
- Direct emissions (scope 1)
- 260 t
- Energy emissions (scope 2)
- 2,692 t
- Value chain emissions (scope 3)
- 4,748 t
- Women in the workforce
- 49.7%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zur Rose Group AG has a strong brand presence and recognition in the pharmaceutical industry.
- The company has a wide range of products and services, providing convenience and accessibility to customers.
- Zur Rose Group AG benefits from economies of scale due to its large customer base and extensive distribution network.
Weaknesses
- Zur Rose Group AG faces intense competition from both traditional brick-and-mortar pharmacies and other online pharmacies.
- The company's profitability is dependent on reimbursement rates from healthcare insurance providers.
- Zur Rose Group AG may also face challenges in gaining customer trust and loyalty due to the sensitive nature of the pharmaceutical industry.
Opportunities
- The growing trend towards e-commerce and digitalization in the healthcare sector provides an opportunity for Zur Rose Group AG to expand its online presence.
- The increasing demand for personalized healthcare services opens avenues for the company to offer tailored product recommendations and improved customer experience.
- Zur Rose Group AG can explore partnerships and collaborations with healthcare providers and insurers to enhance its service offerings.
Threats
- Regulatory changes and compliance requirements pose a significant threat to Zur Rose Group AG's operations and profitability.
- The emergence of counterfeit drugs in the online market can tarnish the company's reputation and erode customer trust.
- Changes in consumer behavior and preferences can impact the demand for online pharmaceutical services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.